Abstract: The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

Abstract: The present disclosure provides compounds of the formula (I): The present disclosure also provides copolymers prepared by polymerizing a first monomer (e.g., dicyclopentadiene) and the compounds. The copolymers may show increased degradability and increased or maintained glass-transition temperature, as compared to homopolymers of the first monomer.

Abstract: Metabolic engineering has developed microbial cell factories as sustainable alternatives to chemical synthesis from petroleum feedstocks or harvesting of animals and plants, but current methods can be a costly and labor-intensive commitment. Methods are described herein for microfluidic methods of screening thousands of variant cells in order to reduce time and uncertainty to provide improved strains.

Abstract: The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

Abstract: Embodiments of the present disclosure relate to methods of preparation of templates for polynucleotide sequencing. In particular, the disclosure relates to linearization of clustered polynucleotides in preparation for sequencing by cleavage of one or more first strands of double-stranded polynucleotides immobilized on a solid support by a transition metal complex, for example, a palladium complex or a nickel complex. Further disclosure relate to linearization of clustered polynucleotides by cleaving one or more second strands of double double-stranded polynucleotides immobilized on a solid support comprising azobenzene linker by Na2S2O4. Nucleotides and oligonucleotides comprising a 3? phosphate moiety blocking group, and methods of removing the same using a fluoride reagent are also disclosed.

Abstract: The present disclosure provides cyclic silyl ethers of the formula: and salts thereof. The cyclic silyl ethers may be useful as monomers for preparing polymers. Also described herein are polymers prepared by polymerizing a cyclic silyl ether and optionally one or more additional monomers. The polymers may be degradable (e.g., biodegradable). One or more O—Si bonds of the polymers may be the degradation sites. Also described herein are compositions and kits including the cyclic silyl ethers or polymers; methods of preparing the polymers; and methods of using the polymers, compositions, and kits.

Abstract: The present disclosure provides copolymers prepared by polymerizing a first monomer comprising at least one C?C and/or at least one C?C; and a second monomer of Formula (B): wherein at least one first monomer and/or at least one second monomer comprises a latent-fluoride moiety (e.g., pentafluorophenyl). Upon contacting the copolymers with a nucleophile (e.g., a thiol) and/or a base, the latent-fluoride moiety may release fluoride ions, which may in turn degrade the copolymers by cleaving the O—Si bonds. The copolymers may be useful for drug delivery, or as degradable (e.g., biodegradable) polymers, adhesives, coatings, or structural materials.

Abstract: An array includes a support including a plurality of discrete wells, a gel material positioned in each of the plurality of discrete wells, and a quality control tracer grafted to the gel material in each of the plurality of discrete wells. The quality control tracer comprises (a) a cleavable nucleotide sequence comprising a cleavage site and (b) a detectable label; and in some aspects, is a cleavable nucleotide sequence with a detectable label and a non-reactive nucleotide sequence or a primer nucleotide sequence.

Abstract: The present disclosure describes functional oligomers or functional polymers. The functional oligomers or functional polymers may contain functional groups, e.g., —OH and/or —CHO. The functional oligomers or functional polymers may be obtained from hydrolyzing certain copolymers and may be soluble in commercially available solvents. The copolymers may be thermosetting polymers. The functional oligomers and functional polymers may be useful for recycling thermosetting polymers and may be useful as starting materials for preparing additional oligomers or polymers.

Abstract: The present disclosure provides compositions comprising: a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: i) a first monomer, wherein each instance of the first monomer is independently of the formula: or salt thereof; ii) a second monomer, wherein each instance of the second monomer is independently of the formula: or a salt thereof; iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and iv) optionally a reprocessing catalyst; and b) optionally the reprocessing catalyst; wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, or a salt thereof; provided that the composition comprises at least one of the reprocessing catalyst of iv) and the reprocessing catalyst of b). The compositions may be reprocessed (e.g., remolded) under elevated temperature and/or elevated pressure.

Abstract: An array includes a support including a plurality of discrete wells, a gel material positioned in each of the plurality of discrete wells, and a quality control tracer grafted to the gel material in each of the plurality of discrete wells. The quality control tracer comprises (a) a cleavable nucleotide sequence comprising a cleavage site and (b) a detectable label; and in some aspects, is a cleavable nucleotide sequence with a detectable label and a non-reactive nucleotide sequence or a primer nucleotide sequence.

Abstract: The present disclosure provides cyclic silyl ethers of the formula: and salts thereof. The cyclic silyl ethers may be useful as monomers for preparing polymers. Also described herein are polymers prepared by polymerizing a cyclic silyl ether and optionally one or more additional monomers. The polymers may be degradable (e.g., biodegradable). One or more O—Si bonds of the polymers may be the degradation sites. Also described herein are compositions and kits including the cyclic silyl ethers or polymers; methods of preparing the polymers; and methods of using the polymers, compositions, and kits.

Abstract: A series of carbohydrate-dye conjugates, as well as a method for detection of pathogenic or other organisms (e.g., bacteria) using the same are provided. The carbohydrate-dye conjugate can be enzymatically incorporated into live and active (viable) bacteria of interest for facile detection of said bacteria. The conjugate incorporation is achieved by utilizing one or more of the enzymes that are endogenous to the bacteria of interest, which can incorporate the conjugate via the conjugate's carbohydrate. A detectable signal is produced by the conjugate's dye only upon incorporation into the bacteria of interest, due to the changes in the dye's local environment upon incorporation. The conjugate may be metabolically incorporated into the fatty outer membrane of a bacterial cell wall, which provides a distinctly hydrophobic environment for the conjugate's dye, causing it to produce a detectable signal.

Abstract: The present disclosure provides compounds of the formula (I): The present disclosure also provides copolymers prepared by polymerizing a first monomer (e.g., dicyclopentadiene) and the compounds. The copolymers may show increased degradability and increased or maintained glass-transition temperature, as compared to homopolymers of the first monomer.

Abstract: A flow cell package includes first and second surface-modified patterned wafers and a spacer layer. The first surface-modified patterned wafer includes first depressions separated by first interstitial regions, a first functionalized molecule bound to a first silane or silane derivative in at least some of the first depressions, and a first primer grafted to the first functionalized molecule in the at least some of the first depressions. The second surface-modified patterned wafer includes second depressions separated by second interstitial regions, a second functionalized molecule bound to a second silane or silane derivative in at least some of the second depressions, and a second primer grafted to the second functionalized molecule in the at least some of the second depressions. The spacer layer bonds at least some first interstitial regions to at least some second interstitial regions, and at least partially defines respective fluidic chambers of the flow cell package.

Abstract: The present disclosure relates to methods for assaying and controlling micro-objects in a microfluidic device. In situ-generated hydrogel barriers are provided for dividing a microfluidic chamber into areas where assaying a cell may be performed without interference from the presence of the cell itself.

Abstract: The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

Abstract: The present disclosure provides compositions comprising: a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: i) a first monomer, wherein each instance of the first monomer is independently of the formula: or salt thereof; ii) a second monomer, wherein each instance of the second monomer is independently of the formula: or a salt thereof; iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and iv) optionally a reprocessing catalyst; and b) optionally the reprocessing catalyst; wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, or a salt thereof; provided that the composition comprises at least one of the reprocessing catalyst of iv) and the reprocessing catalyst of b). The compositions may be reprocessed (e.g., remolded) under elevated temperature and/or elevated pressure.

Abstract: The present disclosure provides cyclic silyl ethers of the formula: and salts thereof. The cyclic silyl ethers may be useful as monomers for preparing polymers. Also described herein are polymers prepared by polymerizing a cyclic silyl ether and optionally one or more additional monomers. The polymers may be degradable (e.g., biodegradable). One or more O—Si bonds of the polymers may be the degradation sites. Also described herein are compositions and kits including the cyclic silyl ethers or polymers; methods of preparing the polymers; and methods of using the polymers, compositions, and kits.

Abstract: A flow cell package includes first and second surface-modified patterned wafers and a spacer layer. The first surface-modified patterned wafer includes first depressions separated by first interstitial regions, a first functionalized molecule bound to a first silane or silane derivative in at least some of the first depressions, and a first primer grafted to the first functionalized molecule in the at least some of the first depressions. The second surface-modified patterned wafer includes second depressions separated by second interstitial regions, a second functionalized molecule bound to a second silane or silane derivative in at least some of the second depressions, and a second primer grafted to the second functionalized molecule in the at least some of the second depressions. The spacer layer bonds at least some first interstitial regions to at least some second interstitial regions, and at least partially defines respective fluidic chambers of the flow cell package.